Ovarian monodermal and highly specialized teratoma

Summary

Ovarian monodermal and highly specialized teratoma (MONDO:0002372) is a disease and 2 clinical trials. Top therapeutic interventions include palbociclib. A subtype of ovarian monodermal teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian monodermal and highly specialized teratoma
Mondo ID	MONDO:0002372
DOID	DOID:2641
NCIT	C8113
UMLS	C0280134
MedGen	83601
GARD	0023125
Is cancer (heuristic)	no

Also known as: ovarian germ cell monodermal and highly specialised teratoma · ovarian germ cell monodermal and highly specialized teratoma · ovarian monodermal and highly specialized teratoma

Disease family

This is a subtype of ovarian monodermal teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › gonadal teratoma › ovarian teratoma › ovarian monodermal teratoma › ovarian monodermal and highly specialized teratoma

Subtypes (1): struma ovarii

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01037790	PHASE2	COMPLETED	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
NCT00060372	PHASE1	COMPLETED	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PALBOCICLIB	4	1